TA Associates, a global private equity firm, agreed to acquire a minority stake in Diatech Pharmacogenetics, a pharmacogenetics and cancer precision medicine diagnostics company, from Alto Partners, a multi-family office. Financial terms were not disclosed. “Diatech’s comprehensive, market-leading product portfolio highlights the Company’s commitment to a rigorous and differentiated R&D process that consistently drives value creation. We look forward to partnering with Fabio, Oliva, and the entire management team to support Diatech’s international and domestic growth journey,” Lovisa Lander, TA Associates Director.